Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL)

February 14, 2025

India

healtysoch

Mahwah, New Jersey/New Delhi, February 14, 2025 :

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). Glenmark’s Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan®2 Ophthalmic Solution, 0.005% of Upjohn US 2 LLC.

According to IQVIATM sales data for the 12-month period ending December 2024, the Xalatan® Ophthalmic Solution, 0.005% market3 achieved annual sales of approximately $113.5 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, “We are excited to announce the launch of our 4th ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), growing our portfolio of products within the ophthalmic channel. This addition highlights our commitment to meeting market needs and providing quality solutions for our customers.”

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

How long after infection do symptoms appear? SARS-CoV-2 (COVID-19)

Are people infectious during this time? India healthysoch New Delhi,

Northwest Syria: WHO raises alarm as more than 50 health facilities are forced to cease operations amid mass displacement and hostilities

Geneva-Cairo-Copenhagen, February 03, 2020: healthysoch The World Health Organization raises alarm